Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience.
Benjamini O, Kantarjian H, Rios MB, Jabbour E, O'Brien S, Jain P, Cardenas-Turanzas M, Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Quintas-Cardama A, Cortes J.
Benjamini O, et al. Among authors: jain p.
Leuk Lymphoma. 2014 Dec;55(12):2879-86. doi: 10.3109/10428194.2013.831092. Epub 2013 Sep 10.
Leuk Lymphoma. 2014.
PMID: 23927391
Free PMC article.